Collaborative overview of randomised trials of antiplatelet therapy - II: Maintenance of vascular graft or arterial patency by antiplatelet therapy
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Objective : To determine the efficacy of antiplatelet therapy in maintaining vascular patency in various categories of patients. Design : Overviews of 46 randomised trials of antiplatelet therapy versus control and 14 randomised trials comparing one antiplatelet regimen with another. Setting : Randomised trials that could have been available by March 1990 and in which vascular graft or arterial patency was to be studied systematically. Subjects : About 8000 patients at varying degrees of risk of vascular occlusion (by virtue of disease or of having some vascular procedure) were in trials of antiplatelet therapy versus control and 4000 such patients were in trials directly comparing different antiplatelet regimens. Results : Overall, antiplatelet therapy produced a highly significant (2P<0.00001) reduction in vascular occlusion, with similar proportional reductions in several different types of patient. Hence the absolute reductions tended to be largest among patients at highest risk of occlusion, with smaller but still significant absolute reductions among lower risk patients. The proportions of patients with confirmed occlusion among those allocated antiplatelet therapy versus appropriately adjusted control proportions (and mean scheduled treatment durations and net absolute benefits) were: (a) among about 4000 patients with coronary artery grafts, 21% antiplatelet therapy v 30% control (seven month benefit about 90 patients protected per 1000 allocated antiplatelet therapy (2P<0.00001); (b) among about 800 patients after coronary angioplasty, 4% antiplatelet therapy upsilion 8% control (six month benefit about 40/1000 (2P = 0.02)); (c) among about 3000 patients with peripheral artery procedures or disease, 16% antiplatelet therapy v 25% control (19 month benefit about 90/1000 (2P<0.00001); (d) among about 400 renal patients with a shunt or fistula placed for haemodialysis access, 17% antiplatelet therapy v 39% control (two month benefit about 200/1000 (2P<0.00001)). Conclusion : Antiplatelet therapy (chiefly aspirin alone or aspirin plus dipyridamole) greatly reduces the risk of vascular occlusion in a wide range of patients at high risk of this complication. Further studies are required to determine exactly when treatment should start (to limit any perioperative bleeding while still preventing most early occlusion) and for how long it should be continued.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiplatelet Trialists' Collaboration (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 3,126
Isolated noncompaction of left ventricular myocardium. A study of eight cases.
Chin, T. K., Perloff, J. K., Williams, R. G., Jue, K., & Mohrmann, R. (1990) · Circulation · doi:10.1161/01.cir.82.2.507 · Cited by 1,418
The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results.
Farrell, B., Godwin, J., Richards, S., & Warlow, C. (1991) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.54.12.1044 · Cited by 1,203
Secondary prevention of vascular disease by prolonged antiplatelet treatment
Antiplatelet Trialists' Collaboration (1988) · BMJ · doi:10.1136/bmj.296.6618.320 · Cited by 1,047
Serruys, P. W., Luijten, H. E., Beatt, K. J., Geuskens, R., de Feyter, P. J., van den Brand, M., Reiber, J. H., ten Katen, H. J., van Es, G. A., & Hugenholtz, P. G. (1988) · Circulation · doi:10.1161/01.cir.77.2.361 · Cited by 931
Percutaneous Transluminal Coronary Angioplasty in 1985–1986 and 1977–1981
Detre, K., Holubkov, R., Kelsey, S., Cowley, M., Kent, K., Williams, D., Myler, R., Faxon, D., Holmes, D., Bourassa, M., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198802043180501 · Cited by 851
Efron, B., & Morris, C. (1977) · Scientific American · doi:10.1038/scientificamerican0577-119 · Cited by 739
Schwartz, L., Bourassa, M. G., Lespérance, J., Aldridge, H. E., Kazim, F., Salvatori, V. A., Henderson, M., Bonan, R., & David, P. R. (1988) · New England Journal of Medicine · doi:10.1056/nejm198806303182603 · Cited by 692
CAMPEAU, L. A., Enjalbert, M., Lespérance, J., Bourassa, M. G., Kwiterovich, P. O., Wacholder, S., & Sniderman, A. D. (1984) · New England Journal of Medicine · doi:10.1056/nejm198411223112101 · Cited by 621
Chesebro, J. H., Clements, I. P., Fuster, V., Elveback, L. R., Smith, H. C., Bardsley, W. T., Frye, R. L., Holmes, D. R., Vlietstra, R. E., Pluth, J. R., et al. (1982) · New England Journal of Medicine · doi:10.1056/nejm198207083070201 · Cited by 537
Cited by
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
Self-citationACC/AHA guidelines for the management of patients with acute myocardial infarction
Committee Members, Ryan, T. J., Anderson, J. L., Antman, E. M., Braniff, B. A., Brooks, N. H., Califf, R. M., Hillis, L. D., Hiratzka, L. F., Rapaport, E., et al. (1996) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(96)00392-0 · Cited by 1,850
Egger, M., Jüni, P., Bartlett, C., Holenstein, F., & Sterne, J. (2003) · Health Technology Assessment · doi:10.3310/hta7010 · Cited by 1,181
Medical treatment of peripheral arterial disease and claudication
Hiatt, W. R. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105243442108 · Cited by 1,121
(2000) · The Lancet · doi:10.1016/s0140-6736(00)02110-3 · Cited by 1,076
Aspirin as an Antiplatelet Drug
Wood, A. J. J., & Patrono, C. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405053301808 · Cited by 955
Profile and prevalence of aspirin resistance in patients with cardiovascular disease
Gum, P. A., Kottke-Marchant, K., Poggio, E. D., Gurm, H., Welsh, P. A., Brooks, L., Sapp, S. K., & Topol, E. J. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01631-9 · Cited by 820
Platelet Glycoprotein IIb/IIIa Receptors in Cardiovascular Medicine
Lefkovits, J., Plow, E. F., & Topol, E. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506083322306 · Cited by 754
Indirect comparisons of competing interventions
Glenny, A., Altman, D., Song, F., Sakarovitch, C., Deeks, J., D'Amico, R., Bradburn, M., & Eastwood, A. (2005) · Health Technology Assessment · doi:10.3310/hta9260 · Cited by 677
Peripheral Arterial Disease in Patients With Diabetes
Marso, S. P., & Hiatt, W. R. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.09.065 · Cited by 575
Mechanical properties of bacterial cellulose and interactions with smooth muscle cells
Bäckdahl, H., Helenius, G., Bodin, A., Nannmark, U., Johansson, B. R., Risberg, B., & Gatenholm, P. (2006) · Biomaterials · doi:10.1016/j.biomaterials.2005.10.026 · Cited by 561
Taylor, D. W., Barnett, H. J., Haynes, R. B., Ferguson, G. G., Sackett, D. L., Thorpe, K. E., Simard, D., Silver, F. L., Hachinski, V., Clagett, G. P., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)05388-x · Cited by 530
Fabre, J.-E., Nguyen, M., Latour, A., Keifer, J. A., Audoly, L. P., Coffman, T. M., & Koller, B. H. (1999) · Nature Medicine · doi:10.1038/13522 · Cited by 439
Belch, J. J. F., & Dormandy, J. (2010) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2010.04.027 · Cited by 363
The aspirin story – from willow to wonder drug
Desborough, M. J. R., & Keeling, D. M. (2017) · British Journal of Haematology · doi:10.1111/bjh.14520 · Cited by 328
Peripheral arterial disease in diabetes—a review
Jude, E. B., Eleftheriadou, I., & Tentolouris, N. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02866.x · Cited by 320
Superiority of Clopidogrel Versus Aspirin in Patients With Prior Cardiac Surgery
Bhatt, D. L., Chew, D. P., Hirsch, A. T., Ringleb, P. A., Hacke, W., & Topol, E. J. (2001) · Circulation · doi:10.1161/01.cir.103.3.363 · Cited by 282
Tissue engineering of small caliber vascular grafts
Hoerstrup, S. (2001) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/s1010-7940(01)00706-0 · Cited by 281
Factors affecting the patency of arteriovenous fistulas for dialysis access
Smith, G. E., Gohil, R., & Chetter, I. C. (2012) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2011.07.095 · Cited by 271
Jack, D. B. (1997) · The Lancet · doi:10.1016/s0140-6736(97)07087-6 · Cited by 256
Qureshi, A. I., Luft, A. R., Sharma, M., Guterman, L. R., & Hopkins, L. N. (2000) · Neurosurgery · doi:10.1097/00006123-200006000-00012 · Cited by 190
Warfarin improves the outcome of infrainguinal vein bypass grafting at high risk for failure
Sarac, T. P., Huber, T. S., Back, M. R., Ozaki, C. K., Carlton, L. M., Flynn, T. C., & Seeger, J. M. (1998) · Journal of Vascular Surgery · doi:10.1016/s0741-5214(98)70130-2 · Cited by 172
Principles From Clinical Trials Relevant to Clinical Practice: Part I
Califf, R. M., & DeMets, D. L. (2002) · Circulation · doi:10.1161/01.cir.0000023260.78078.bb · Cited by 108
Umbrella review and meta-analysis of antiplatelet therapy for peripheral artery disease
Ambler, G. K., Waldron, C.-A., Contractor, U. B., Hinchliffe, R. J., & Twine, C. P. (2020) · Journal of British Surgery · doi:10.1002/bjs.11384 · Cited by 35
Mannava, K., & Money, S. R. (2007) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200707010-00005 · Cited by 22
Medical Treatment of Peripheral Artery Disease
Gornik, H. L., & Creager, M. A. (2013) · Vascular Medicine: A Companion to Braunwald's Heart Disease · doi:10.1016/b978-1-4377-2930-6.00019-7 · Cited by 12
Metadata
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 1994-01-15
- Volume
- 308
- Issue
- 6922
- Pages
- 159-168
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W4231595983
- Cited by
- 510
- References
- 42
- FWCI
- 20.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.